Vaxart Lands $4,368,419 New Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    20 California Street 7th Floor San Francisco, CA 94111
  • Company Description
    The combination of adenovirus vector, adjuvant and oral administration will unlock the potential of vector-based vaccination, with applications in Avian Influenza response, biodefense vaccines, and second-generation versions of existing vaccines. The company is currently testing an avian flu vaccine.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing-amended.
  • M&A Terms
  • Venture Investor

Trending on Xconomy